Literature DB >> 19703479

Monoaminergic neuronal changes in orexin deficient mice.

Tomohisa Mori1, Shinobu Ito, Tomoyuki Kuwaki, Masashi Yanagisawa, Takeshi Sakurai, Toshiko Sawaguchi.   

Abstract

Orexin knockout (KO) mice and orexin/ataxin-3 mice (which have a different pathophysiological background in orexin deficiency) exhibit a phenotype that is similar to human narcolepsy. Although the interactions between the monoaminergic and orexinergic systems are not entirely clear, indirect monoamine-receptor agonists (especially psychostimulants) may contribute to the treatment of narcolepsy. The present study was designed to investigate the interaction between brain orexinergic and monoaminergic neurons as measured by the status of monoaminergic systems and monoamine-related behaviors using orexin-deficient mice. Previous studies have shown that a reduction of monoaminergic tone is related to wakefulness. In the present study, locomotor activity in a novel environment and dopamine turnover was significantly decreased in orexin-deficient mice compared to WT mice, which suggests that psychostimulants may be useful for maintaining wakefulness in orexin deficiency. We also examined the effects of orexin deficiency on psychostimulant-induced hyperlocomotion. The hyperlocomotion induced by methamphetamine and methylphenidate was lower, whereas that induced by MDMA was higher in orexin KO mice compared to WT mice. The sensitivities against psychostimulants in orexin/ataxin-3 mice differed from those in orexin KO mice. These results indicate that the effectiveness of each psychostimulant, which is closely related to its monoaminergic function, was influenced by orexin deficiency itself as well as by the different pathophysiological background in orexin deficiency. Copyright 2009. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703479     DOI: 10.1016/j.neuropharm.2009.08.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Neurochemical heterogeneity of rats predicted by different measures to be high ethanol consumers.

Authors:  Jessica R Barson; Shawn E Fagan; Guo-Qing Chang; Sarah F Leibowitz
Journal:  Alcohol Clin Exp Res       Date:  2012-06-22       Impact factor: 3.455

Review 2.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice.

Authors:  Tomomi Tsunematsu; Thomas S Kilduff; Edward S Boyden; Satoru Takahashi; Makoto Tominaga; Akihiro Yamanaka
Journal:  J Neurosci       Date:  2011-07-20       Impact factor: 6.167

5.  Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.

Authors:  Ming-Fung Wu; Robert Nienhuis; Nigel Maidment; Hoa A Lam; Jerome M Siegel
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

6.  The effects of amphetamine injections on feeding behavior and the brain expression of orexin, CART, tyrosine hydroxylase (TH) and thyrotropin releasing hormone (TRH) in goldfish (Carassius auratus).

Authors:  Hélène Volkoff
Journal:  Fish Physiol Biochem       Date:  2012-12-11       Impact factor: 2.794

7.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

8.  Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT.

Authors:  Tomohisa Mori; Naoki Uzawa; Yoshiyuki Iwase; Daiki Masukawa; Mahardian Rahmadi; Shigeto Hirayama; Mayuna Hokazono; Kimio Higashiyama; Seiji Shioda; Tsutomu Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2016-04-11       Impact factor: 4.530

9.  Different levels in orexin concentrations and risk factors associated with higher orexin levels: comparison between detoxified opiate and methamphetamine addicts in 5 Chinese cities.

Authors:  Haoran Zhang; Zhi Lian; Shiyan Yan; Yanping Bao; Zhimin Liu
Journal:  Biomed Res Int       Date:  2013-09-12       Impact factor: 3.411

Review 10.  Genes and primary headaches: discovering new potential therapeutic targets.

Authors:  Innocenzo Rainero; Elisa Rubino; Koen Paemeleire; Annalisa Gai; Alessandro Vacca; Paola De Martino; Salvatore Gentile; Paola Sarchielli; Lorenzo Pinessi
Journal:  J Headache Pain       Date:  2013-07-12       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.